Blood thinnerFDA-approvedAdjuvant
Eliquis
Generic name: apixaban
How it works
Blocks the action of certain clotting factors in the blood, reducing the risk of blood clots.
Cancer types
Lung Cancer— All patients
Efficacy
Studies show that apixaban reduces the risk of recurrent venous thromboembolism in patients with cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Apixaban Reduces Blood Clots in Obese Kids with Leukemia | Leukemia | phase-3 | A significant decrease in VTE events was present in the apixaban arm (1/42 [2.4%]) as compared with the SOC arm (10/40 [25%]). | Source → |
| Apixaban May Be Better Than Enoxaparin for Preventing Blood Clots After Surgery | Colorectal Cancer | observational | Rates of VTE are low in both groups, but significantly higher in those who received enoxaparin than those who received apixaban (1.29% versus 0.16%, P = 0.023). | Source → |
| Furmonertinib Affects Blood Thinners in Lab Experiments | Lung Cancer | animal-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.